Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
Amgen is halting deliveries of an unrivalled psoriatic arthritis treatment to the Russian Federation
- By Newsdesk
- Russia
- May 26, 2023
Amgen, a pharmaceutical company based in the United States, has announced that it will no longer ship Otesla (apremilast) to Russia. According to Vademecum, the active substance apremilast is included in the Vital and Essential Drugs and profile clinical recommendations and has no analogues in Russia.
The pharmaceutical company informed Roszdravnadzor of its decision, and the agency, in turn, warned of a high risk of a defect in the apremilast of the Russian Federation's Ministry of Health's chief freelance specialist, rheumatologist Evgeny Nasonov.
The lack of apremilast, however, will not be a problem, according to Alexander Lila, Director of the Research Institute of Rheumatology named after V. A. Nasonova. The substance is part of a class of targeted synthetic drugs that includes tofacitinib (the original "Jaquinus" from Pfizer). Anti-inflammatory drugs, such as Methotrexate or Sulfasalazine, are also used to treat the diseases for which Otesla is prescribed.
Otesla is also approved for the treatment of moderate to severe plaque psoriasis and Behçet's disease, in addition to psoriatic arthritis.